Triple agonist (GLP-1 / GIP / glucagon) showing ~24% mean body weight reduction at 48 weeks in Phase 2 trials — the largest weight-loss effect of any GLP-1 class compound to date.
Pre-filled with standard Retatrutide values. Adjust as needed.
Titration: start 2mg weekly for 4 wks, then titrate up 2mg every 4 wks to 8–12mg maintenance. Research-only; not FDA-approved. Track glucose, ApoB, LFTs monthly.
Blood markers to track
Note: Not FDA-approved. In Phase 3 trials under brand name Maridebart. Triple agonist — GLP-1 + GIP + glucagon. Expected FDA filing 2026. Increases heart rate ~4-6 bpm — monitor in cardiovascular patients.
Log every Retatrutide injection alongside your HbA1c and Fasting glucose readings. Compare draws over time in your free dashboard — so the next change you make is based on your numbers, not a guess.
Start tracking Retatrutide free →No credit card · Free forever tier